Gut Mycobiome in Metabolic Diseases: Mechanisms and Clinical Implication

Overview

Journal Biomed J

Publisher Elsevier

Specialty General Medicine

Date 2023 Jun 26

PMID 37364760

Authors

Xingyu Zhou

Xiang Zhang

Jun Yu

Affiliations

Soon will be listed here.

Abstract

Obesity, type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are three common metabolic diseases with high prevalence worldwide. Emerging evidence suggests that gut dysbiosis may influence the development of metabolic diseases, in which gut fungal microbiome (mycobiome) is actively involved. In this review, we summarize the studies exploring the composition changes of gut mycobiome in metabolic diseases and mechanisms by which fungi affect the development of metabolic diseases. The current mycobiome-based therapies, including probiotic fungi, fungal products, anti-fungal agents and fecal microbiota transplantation (FMT), and their implication in treating metabolic diseases are discussed. We highlight the unique role of gut mycobiome in metabolic diseases, providing perspectives for future research on gut mycobiome in metabolic diseases.

Citing Articles

Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases.

Wang Y, Xu H, Zhou X, Chen W, Zhou H Med Rev (2021). 2024; 4(4):262-283.

PMID: 39135605 PMC: 11317083. DOI: 10.1515/mr-2024-0020.

Effect of the gut microbiome, plasma metabolome, peripheral cells, and inflammatory cytokines on obesity: a bidirectional two-sample Mendelian randomization study and mediation analysis.

Li Y, Wang X, Zhang Z, Shi L, Cheng L, Zhang X Front Immunol. 2024; 15:1348347.

PMID: 38558794 PMC: 10981273. DOI: 10.3389/fimmu.2024.1348347.

References

Dufosse L, Fouillaud M, Caro Y . Fungi and Fungal Metabolites for the Improvement of Human and Animal Nutrition and Health. J Fungi (Basel). 2021; 7(4). PMC: 8066858. DOI: 10.3390/jof7040274. View

Noverr M, Phare S, Toews G, Coffey M, Huffnagle G . Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect Immun. 2001; 69(5):2957-63. PMC: 98248. DOI: 10.1128/IAI.69.5.2957-2963.2001. View

Vandanmagsar B, Youm Y, Ravussin A, Galgani J, Stadler K, Mynatt R . The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011; 17(2):179-88. PMC: 3076025. DOI: 10.1038/nm.2279. View

Shoukat M, Ullah F, Tariq M, Din G, Khadija B, Faryal R . Profiling of potential pathogenic candida species in obesity. Microb Pathog. 2022; 174:105894. DOI: 10.1016/j.micpath.2022.105894. View

Cao Y, Sun Y, Zou S, Li M, Xu X . Orally Administered Baker's Yeast β-Glucan Promotes Glucose and Lipid Homeostasis in the Livers of Obesity and Diabetes Model Mice. J Agric Food Chem. 2017; 65(44):9665-9674. DOI: 10.1021/acs.jafc.7b03782. View

Al Bataineh M, Dash N, Bel Lassen P, Banimfreg B, Nada A, Belda E . Revealing links between gut microbiome and its fungal community in Type 2 Diabetes Mellitus among Emirati subjects: A pilot study. Sci Rep. 2020; 10(1):9624. PMC: 7295773. DOI: 10.1038/s41598-020-66598-2. View

Kusmiati , Dhewantara F . Cholesterol-Lowering Effect of Beta Glucan Extracted from Saccharomyces cerevisiae in Rats. Sci Pharm. 2016; 84(1):153-65. PMC: 4839553. DOI: 10.3797/scipharm.ISP.2015.07. View

Conti H, Shen F, Nayyar N, Stocum E, Sun J, Lindemann M . Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 2009; 206(2):299-311. PMC: 2646568. DOI: 10.1084/jem.20081463. View

Garcia-Gamboa R, Kirchmayr M, Gradilla-Hernandez M, Perez-Brocal V, Moya A, Gonzalez-Avila M . The intestinal mycobiota and its relationship with overweight, obesity and nutritional aspects. J Hum Nutr Diet. 2021; 34(4):645-655. DOI: 10.1111/jhn.12864. View

10.

Yang A, Lin C, Liu S, Syu G, Sun H, Lee K . Ameliorates Non-alcoholic Steatohepatitis in Mice Induced by a Methionine-Choline-Deficient Diet Through Gut-Liver Axis. Front Microbiol. 2022; 13:887728. PMC: 9260146. DOI: 10.3389/fmicb.2022.887728. View

11.

Mosikanon K, Arthan D, Kettawan A, Tungtrongchitr R, Prangthip P . Yeast β-Glucan Modulates Inflammation and Waist Circumference in Overweight and Obese Subjects. J Diet Suppl. 2016; 14(2):173-185. DOI: 10.1080/19390211.2016.1207005. View

12.

Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

13.

Nash A, Auchtung T, Wong M, Smith D, Gesell J, Ross M . The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome. 2017; 5(1):153. PMC: 5702186. DOI: 10.1186/s40168-017-0373-4. View

14.

Wang W, Zhong X, Guo J . Role of 2‑series prostaglandins in the pathogenesis of type 2 diabetes mellitus and non‑alcoholic fatty liver disease (Review). Int J Mol Med. 2021; 47(6). PMC: 8083810. DOI: 10.3892/ijmm.2021.4947. View

15.

Erb-Downward J, Noverr M . Characterization of prostaglandin E2 production by Candida albicans. Infect Immun. 2007; 75(7):3498-505. PMC: 1932954. DOI: 10.1128/IAI.00232-07. View

16.

Mridha A, Wree A, Robertson A, Yeh M, Johnson C, Van Rooyen D . NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017; 66(5):1037-1046. PMC: 6536116. DOI: 10.1016/j.jhep.2017.01.022. View

17.

Mims T, Al Abdallah Q, Stewart J, Watts S, White C, Rousselle T . The gut mycobiome of healthy mice is shaped by the environment and correlates with metabolic outcomes in response to diet. Commun Biol. 2021; 4(1):281. PMC: 7935979. DOI: 10.1038/s42003-021-01820-z. View

18.

Sudun , Wulijideligen , Arakawa K, Miyamoto M, Miyamoto T . Interaction between lactic acid bacteria and yeasts in airag, an alcoholic fermented milk. Anim Sci J. 2013; 84(1):66-74. DOI: 10.1111/j.1740-0929.2012.01035.x. View

19.

Wu C, Lin H, Wu G, Wang S, Tsai G . Effects of cultural medium and conditions on the proliferation and hypoglycemic activity of Saccharomyces pastorianus no. 54. J Biosci Bioeng. 2011; 112(2):159-65. DOI: 10.1016/j.jbiosc.2011.04.012. View

20.

Vrieze A, van Nood E, Holleman F, Salojarvi J, Kootte R, Bartelsman J . Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012; 143(4):913-6.e7. DOI: 10.1053/j.gastro.2012.06.031. View